NCI scientist to receive award for achievement in cancer research
Click Here to Manage Email Alerts
Steven A. Rosenberg, MD, PhD, FAACR, will receive this year’s Pezcoller Foundation-American Association of Cancer Research International Award for Extraordinary Achievement in Cancer Research.
The award recognizes a scientist who has made a major scientific discovery in basic or translational cancer research, remains active in cancer research, and is conducting ongoing work that offers promise for continued substantive contributions to progress in cancer.
Rosenberg will be honored for his discovery and development of interleukin-2 — the first FDA-approved immunotherapy for people with cancer — as well as for his contributions to the development of chimeric antigen receptor T-cell therapies and other cellular therapies.
He will receive the award at this year’s AACR Annual Meeting, scheduled for April 8-13 in New Orleans.
“We are extremely proud to honor Dr. Rosenberg,” Margaret Foti, PhD, MD (hc), CEO of AACR, said in an association-issued press release. “His pioneering research in immunotherapy has created a new paradigm for the treatment of cancer and other diseases, and has resulted in countless lives being saved. He could not be more deserving to receive our most prestigious of scientific achievement awards.”
Rosenberg is senior investigator in NCI’s Center for Cancer Research. He also is chief of NCI’s Surgery Branch and professor of surgery at George Washington University School of Medicine and Health Sciences.
Click Here to Manage Email Alerts